SOHO 2026 | Targeting aurora kinase A in blast-phase CML: how close are clinical trials?
Simona Soverini, PhD, University of Bologna, Bologna, Italy, discusses the potential clinical implications of targeting aurora kinase A (AURKA) in blast-phase chronic myeloid leukemia (CML). Dr Soverini emphasizes that data are currently limited to the preclinical setting but highlights AURKA inhibitors, particularly in combination with BCR::ABL1 tyrosine kinase inhibitors, as a potential strategy for patients with few remaining therapeutic options. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, we believe that our data are interesting but are still confined to the preclinical level. Of course, for blast crisis patients the therapeutic options are quite limited and we are always looking for new drugs or drug combinations to try on these patients. So probably I would foresee that a combination of an aurora kinase inhibitor and a BCR::ABL1 inhibitor, or in case of those aurora kinase inhibitors that are also BCR::ABL1 kinase inhibitors, I think it could be an interesting option to be tested on patients...
Well, we believe that our data are interesting but are still confined to the preclinical level. Of course, for blast crisis patients the therapeutic options are quite limited and we are always looking for new drugs or drug combinations to try on these patients. So probably I would foresee that a combination of an aurora kinase inhibitor and a BCR::ABL1 inhibitor, or in case of those aurora kinase inhibitors that are also BCR::ABL1 kinase inhibitors, I think it could be an interesting option to be tested on patients. Sometimes it’s not easy to repurpose one of these inhibitors, it depends on the local regulations, but I’m very much eager to see whether this may work in some cases in which we have run out of all the possible therapeutic options.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
